WO2001023345A1 - Procede de preparation de derive piperazine - Google Patents
Procede de preparation de derive piperazine Download PDFInfo
- Publication number
- WO2001023345A1 WO2001023345A1 PCT/JP2000/006650 JP0006650W WO0123345A1 WO 2001023345 A1 WO2001023345 A1 WO 2001023345A1 JP 0006650 W JP0006650 W JP 0006650W WO 0123345 A1 WO0123345 A1 WO 0123345A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- formula
- reaction
- solution
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/74—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/04—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reaction of ammonia or amines with olefin oxides or halohydrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
Definitions
- the present invention relates to a method for producing a piperazine derivative. More specifically, the present invention relates to a method for producing a piperazine derivative which can be suitably used as an intermediate for producing mirtazapine useful as an antidepressant.
- Conventional technology relates to a method for producing a piperazine derivative which can be suitably used as an intermediate for producing mirtazapine useful as an antidepressant.
- Mirtazapine is a compound useful as an antidepressant.
- a piperazine derivative has been known as an intermediate for producing mirtazapine.
- a method for producing a piperazine derivative a method is known in which 1-methyl-13-phenylbiperazine is reacted with 2-chloro-3-cyanopyridine in the presence of potassium fluoride (Japanese Patent Publication No. No. 9-426678).
- An object of the present invention is to provide a piperazine derivative useful as an intermediate for producing mirtazapine and an important intermediate for producing mirtazapine without the need for complicated operations.
- An object of the present invention is to provide a method for industrially and easily producing 1-methyl-3-phenylbiperazine. Disclosure of the invention
- (1) comprising reacting styrene oxide with N-methylethanolamine in an aprotic polar organic solvent, comprising:
- Formula (III) comprising: salting the diol compound obtained in the above (1) with an acid, and then subjecting the salt to a chlorinated compound.
- FIG. 1 is a photomicrograph of 2- (4-methyl-2-phenenylbiperazine-11-yl) -13-cyanopyridine oxalate obtained in Example 11; BEST MODE FOR CARRYING OUT THE INVENTION
- the amount of N-methylethanolamine is not particularly limited, but is usually about 0.8 to 1.2 mol per mol of styrene oxide in consideration of economy and post-reaction treatment. Is preferred.
- aprotic polar organic solvent examples include dimethylformamide, dimethylethylacetamide, dimethylsulfoxide, 1,3-dimethylimidazolidin-2-one, N-methyl-2-pyrrolidone, and the like. These can be used alone or in combination of two or more. Among them, dimethylformamide and 1,3-dimethylimidazolidin-2-one can be suitably used in the present invention.
- the amount of the aprotic polar organic solvent is not particularly limited, it is usually about 100 to 600 parts by volume, preferably about 150 to 400 parts by volume, based on 100 parts by weight of styrene oxide. It is desirable that
- the reaction is preferably carried out by dropping N-methylethanolamine into styrene oxide.
- the reaction temperature is preferably 50 ° C. or higher, preferably 70 ° C. or higher, and more preferably 80 ° C. or higher, from the viewpoint of accelerating the reaction. It is desirable that the temperature be 120 ° C. or lower, and more preferably 100 ° C. or lower, since a product is generated.
- the atmosphere during the reaction is not particularly limited.
- the atmosphere may be air, for example, an inert gas such as nitrogen gas.
- the reaction time is not particularly limited, but is usually about 2 to 5 hours.
- the end point of the reaction is
- the time can be set to the time when the area percentage of N-methylethanolamine becomes 0.5% or less by gas chromatography or the like.
- the diol compound can be converted to a dichloro compound by subjecting the diol compound to chlorination.
- the diol compound be converted to a salt before the chlorination, from the viewpoint of reducing the amount of by-products and facilitating the reaction.
- Examples of a method for converting a diol compound into a salt include a method of introducing an acid [H X in the formula (I U)] into a reaction solution containing the generated diol compound.
- Acids that can be suitably used to convert the diol compound into a salt include hydrochloric acid (hydrogen chloride gas), hydrobromic acid, mesylic acid, besylic acid, p-toluenesulfonic acid and the like. Of these, hydrochloric acid (hydrogen chloride gas), mesylic acid and besylic acid are preferred, and hydrochloric acid (hydrogen chloride gas) and mesylic acid are more preferred.
- the amount of the acid is preferably at least 1 equivalent to 1 equivalent of the diol compound, and more preferably 1.0 to 1.2 equivalent to the diol compound in order to sufficiently convert the diol compound into a salt.
- diol compound or a salt of the diol compound (hereinafter, both are collectively referred to as a diole compound (salt)) are converted into a clopohydrate.
- the reaction solution is used without isolation of the diol compound (salt) from the reaction solution containing the diol compound (salt) obtained above. can do.
- the diol compound (salt) can be chromatized using, for example, a clotting agent such as thionyl chloride, phosphorus oxychloride, oxalyl chloride, and phosgene.
- a clotting agent such as thionyl chloride, phosphorus oxychloride, oxalyl chloride, and phosgene.
- the amount of the clotting agent is not particularly limited, but is usually about 2 to 3.5 equivalents, preferably about 2 to 3 equivalents per equivalent of the diol compound (salt).
- the lipolysis of a diol compound (salt) using a clotting agent can be performed, for example, by mixing the clotting agent with the reaction solution obtained above and stirring appropriately, or by adding , Dimethylformamide, 1,3-dimethylimidazolidine-12-one or the like, dissolved in an organic solvent, and mixed with the organic solvent solution of the clotting agent and the reaction solution obtained in the above, It can be easily performed by stirring appropriately.
- the amount of the organic solvent is usually preferably about 100 to 500 parts by weight based on 100 parts by weight of the clotting agent.
- the diol compound (salt) can be easily prepared by dropping the diol compound (salt) into the chlorinating agent at 0 to 30 ° C.
- the time required for the diol compound (salt) to be converted into chromium is not particularly limited, but is usually about 1 to 12 hours. Further, the end point of the chromatization can be easily confirmed by, for example, gas chromatography. In this way, by subjecting the diol compound (salt) to a cyclochlorination, a dichloro compound represented by the formula (II) or a salt of the dichloro compound represented by the formula ( ⁇ ) can be obtained.
- the obtained reaction solution containing the dichloro compound or a salt of the dichloro compound is first added to water in order to remove a water-soluble organic solvent such as a clotting agent such as thionyl chloride and dimethylformamide.
- a water-soluble organic solvent such as a clotting agent such as thionyl chloride and dimethylformamide.
- the reaction solution is added dropwise.
- the amount of water is usually
- the amount is preferably 100 to 300 parts by weight based on 100 parts by weight of a water-soluble organic solvent such as dimethylformamide.
- the dropping temperature is usually from 0 to 30 ° C, preferably from 0 to 25 ° C.
- an alkaline aqueous solution is added dropwise to the reaction solution, and the pH is adjusted to 0.8 to 1.0.
- a potassium hydroxide aqueous solution or a sodium hydroxide aqueous solution having a concentration of 10 to 40% by weight can be used as the alkaline aqueous solution.
- Dropping temperature 0 ⁇ 2 5 ° C, it is desirable that preferably 0 to 2 0 e C. It is preferable that the alkaline aqueous solution be cooled to 5 to 10 ° C. in advance.
- an alkaline aqueous solution is added to the reaction solution so that the pH of the reaction solution is 4 to 5.
- the aqueous alkaline solution preferably flows at a temperature of 0 to 25 ° C.
- an ether-based solvent such as diisopropyl ether, an ester-based solvent such as ethyl acetate or butyl acetate, or a hydrocarbon-based solvent such as toluene, preferably toluene is desirable. If necessary, washing can be carried out, dried over anhydrous magnesium sulfate, anhydrous sodium sulfate, or the like, and activated clay can be added thereto.
- the reaction of the dichloro compound or a salt of the dichloro compound [hereinafter, referred to as a dichloro compound (salt)] with ammonia can be performed, for example, in a solvent.
- the solvent is selected from, for example, aprotic polar organic solvents such as dimethylformamide; hydrocarbon solvents such as toluene; ester solvents such as ethyl acetate and butyl acetate; and ether solvents such as diisopropyl ether.
- aprotic polar organic solvents such as dimethylformamide
- hydrocarbon solvents such as toluene
- ester solvents such as ethyl acetate and butyl acetate
- ether solvents such as diisopropyl ether.
- One or more solvents described above can be suitably used. Among them, a mixed solvent of dimethylformamide and toluene is preferred.
- the amount of the solvent is usually 100 to 100 parts by volume, preferably 120 to 800 parts by volume, based on 100 parts by weight of the dichloro compound (salt).
- Ammonia may be directly blown into the solvent in a gaseous state, or may be dissolved in water and used as ammonia water.
- the ammonia concentration in the aqueous ammonia is usually preferably about 15 to 28%.
- the amount of ammonia is from 10 to 50 mol, preferably from 15 to 30 mol, more preferably from 20 to 30 mol, per mol of the dichloro compound (salt). It is desirable from the viewpoint of economy.
- a dichloro compound (salt) with ammonia it is preferable to use a quaternary ammonium salt from the viewpoint of promoting the reaction by phase transfer.
- quaternary ammonium salts include tetrabutylammonium bromide, benzyltrimethylammonium chloride, benzyltrimethylammonium bromide, benzyltriethylammonium chloride, bromide Benzylethylammonium, tricaprylmethylammonium chloride, tetrabutylammonium iodide and the like can be mentioned, and these can be used alone or in combination of two or more.
- the amount of the quaternary ammonium salt is preferably from 200 to 111 £ to 508, more preferably from 200 to 118, and more preferably from 200 to 111 mol per mole of the dichloro compound (salt). It is preferably 1 to 30 g.
- the temperature at which the dichloro compound (salt) is reacted with ammonia is not particularly limited, but is usually from 10 to 80, preferably from 20 to 50 ° C, and more preferably from 30 to 50 ° C. C is desirable.
- the reaction time is not particularly limited, but is usually about 1 to 10 hours.
- the end point of the reaction can be easily confirmed by, for example, high performance liquid chromatography, gas chromatography and the like.
- aqueous solution of sodium hydroxide or the like is added to the thus obtained reaction solution containing 1-methyl-3-phenylphenylperazine represented by the formula (IV) to make the solution more alkaline.
- concentration of the aqueous alkali solution is preferably about 20 to 50% by weight.
- the reaction solution may be alkaline, for example, the pH may be about 11 to 12.
- the alkalinized solution is, for example, toluene, ethyl acetate, ether, and the like, preferably at least once with toluene.
- 1-methyl-3-phenylbiperazine can be isolated by a method such as distillation.
- perazine-1-yl) -13-cyanopyridine can be accomplished, for example, by reacting 1-methyl-13-phenylbiperazine with 2-chloro-13-cyanopyridine in the presence of a base and an alkali metal halide.
- the reaction can be easily carried out by reacting in a protic polar organic solvent.
- the amount of 1-methyl-3-phenylbiperazine is 0.7 from the viewpoint of sufficiently proceeding the reaction with 2-chloro-3-cyanopyridin, relative to 1 mol of 2-cyclo-3-cyanopyridine. It is desirably from 0.1 to 1.1 mol, preferably from 0.8 to 1.1 mol, and more preferably from 0.8 to 0 mol.
- an aprotic polar organic solvent is used.
- the non-protonic polar organic solvent include dimethylformamide, dimethylacetamide, dimethylsulfoxide, 1,3-dimethylimidazolidin-1-one, and the like. Among these, dimethylformamide can be suitably used.
- the amount of the solvent is not particularly limited, it is usually 100 to 800 parts by volume, preferably 150 to 50 parts by weight, per 100 parts by weight of 1-methyl-3-phenylbiperazine. It is desirably 0 parts by volume.
- a base is used to promote the reaction and suppress the generation of by-products.
- the base include alkylamines such as triethylamine and diisopropylethylamine; cyclic amines such as N-methylmorpholine; organic bases such as allylamine such as pyridine and picoline; and inorganic bases such as potassium carbonate and sodium carbonate.
- the amount of the base is from 0.5 to 20 moles per mole of 2-chloro-3-cyanopyridine from the viewpoint of rapidly proceeding the reaction between 1-methyl-3-phenylbiperazine and 2-chloro-3-cyanopyridine. Preferably, it is 0.7 to 2 mol.
- an alkali metal halide is used to promote the reaction.
- the alkali metal halide include potassium iodide and sodium iodide.
- the amount of alkali metal halide depends on its solubility and From the viewpoints of economy and economy, it is desirable that the amount is 0.05 to 1.5 mol, preferably 0.07 to 2 mol, per 1 mol of 2-chloro-3-cyanopyridine.
- an appropriate amount of a quaternary ammonium salt such as tetrabutylammonium iodide, tetrabutylammonium bromide, benzyltrimethylammonium chloride, or the like may be used as the catalyst. Good.
- the reaction between 1-methyl-3-phenylbiperazine and 2-chloro-1-cyanopyridine is preferably carried out in an inert gas such as nitrogen gas or argon gas.
- the reaction temperature is usually 90 to 160 ° C, preferably 110 to 150 ° C, from the viewpoint of improving the reaction rate and suppressing the generation of by-products. desirable.
- the reaction time cannot be determined unconditionally because it depends on the reaction temperature, but it is usually about 12 to 24 hours.
- the reaction was refluxed at a reaction temperature of 110 to 125 ° C for 8 to 12 hours, and a low volatile fraction was distilled off at 125 to 135 ° C.
- the reaction may be performed under the reaction conditions of heating at 40 ° C. for 5 to 10 hours.
- 2- (4-Methyl-2-phenylvinylperazine-1-yl) -13-cyanopyridine which is a piperazine derivative represented by the following formula, can be easily isolated.
- the reaction solution was heated at an internal temperature of 70 to 95 and at a reduced pressure of 7 to 2.7 kPa, and 75 to 95% of the dimethylformamide used was distilled off to 70 to 80.
- 100 to 250 parts by weight of water is added to 100 parts by weight of 1-methyl-3 monophenylbiperazine.
- the pH is adjusted to 8 to 9 with alkali.
- the alkali include sodium hydroxide and sodium carbonate. When sodium hydroxide is used as the alkali, it can be usually used as a 10 to 40% by weight aqueous sodium hydroxide solution.
- the reaction solution is extracted with ethyl acetate.
- the amount of ethyl acetate is preferably from 300 to 150 parts by weight based on 100 parts by weight of 1-methyl-3-phenylbiperazine. Further, the extraction temperature is preferably 40 to 50 ° C.
- the produced 2- (4-methyl-2-phenylbiperazin-1-yl) -13-cyanopyridine is dissolved in an organic solvent such as ethyl acetate, methanol or ethanol, and an acid is added thereto. Added, filtered, dried and the resulting salt of 2- (4-methyl-12-phenylbiperazine-11-yl) -13-cyanopyridine can be used as a piperazine derivative.
- the acid for example, organic acids such as oxalic acid, succinic acid, maleic acid, methanesulfonic acid, and toluenesulfonic acid, and inorganic acids such as sulfuric acid, hydrochloric acid, and phosphoric acid can be used.
- organic acids such as oxalic acid, succinic acid, maleic acid, methanesulfonic acid, and toluenesulfonic acid
- inorganic acids such as sulfuric acid, hydrochloric acid, and phosphoric acid.
- oxalic acid is preferred from the viewpoint of crystallinity, purity and yield.
- oxalic acid 100 parts by weight of 1-methyl-3-phenylpyrazine is added to a solution containing 2- (4-methyl-2-phenylbiperazine-11-yl) -3-cyanopyridine extracted from the reaction solution.
- oxalic acid 100 parts by weight of oxalic acid, or 100 to 150 parts by weight of methanol and 100 to 50 parts by weight of oxalic acid.
- a solution in which oxalic acid is dissolved in methanol at a ratio of about 400 parts by weight may be dropped.
- the amount of oxalic acid is preferably 0.9 to 1.5 mol per 1 mol of 1-methyl-3-phenylbiperazine.
- the solution is cooled to 15 to 25 ° C, aged for 10 to 10 hours, filtered, and a mixed solvent of methanol and ethyl acetate (for example, ethyl acetate acetate per 1 part by volume of methanol) 3 to 4 parts by volume). Thereafter, by drying at a drying temperature of 50 to 60 ° C., the formula (VI):
- Styrene oxide 25 g, 0.2 mol was added to dimethylformamide (50 ml), and N-methylethanolamine (14.3 g, 0.19 mol) was added dropwise at 80 ° C. The mixture was stirred at 80 for 3 hours, the end point of the reaction was confirmed by gas chromatography, and the mixture was cooled.
- reaction solution was added dropwise to a solution obtained by dissolving 45 kg of thionyl chloride in 67.4 kg of toluene. Thereafter, the mixture was stirred at 45 to 55 for 2 hours.
- reaction solution After cooling the obtained reaction solution to 25 ° C or lower, 95 kg of water is added dropwise to the reaction solution, and then 50.8 kg of a 30% by weight aqueous hydration solution is added dropwise at 20 to 25 ° C. The mixture was allowed to stand still and liquid was separated.
- reaction solution was separated, and the aqueous layer was extracted twice with 30 ml of ethyl acetate at 40 to 45 ° C, and the organic layers were combined. Thereafter, the organic layer was distilled under reduced pressure to obtain 7.1 g of a product (yield from the hydrochloride of the diclo-mouth compound 53.8%).
- the container containing the mixed solution was washed with 70.8 kg of toluene, added to the reaction solution, and stirred at 45 to 52 for 2 hours. Analysis by gas chromatography revealed that N- (2-hydroxyethyl) -1-N-methyl-hydroxy-1-phenyl After confirming that the ethylamine had disappeared, the reaction solution was cooled to about 10 ° C., and added dropwise to 998 kg of water over 2 to 29 to hydrolyze excess thionyl chloride.
- the reactor was washed with 105.3 kg of toluene, and the washing solution was added to the hydrolysis solution.
- a 25% aqueous sodium hydroxide solution is added dropwise until the pH becomes 1, and at 6 to 25 ° C, a 25% aqueous sodium hydroxide solution is added until the pH becomes 4.2 (1073 kg).
- the organic layer was separated, the aqueous layer was extracted with 71 1 kg of toluene, and the organic layers were combined.
- 71.4 kg of activated clay V2 (trade name, manufactured by Mizusawa Chemical Co., Ltd.) was added, the mixture was decolorized, and then filtered.
- the mixture was stirred at 40 to 44 ° C for 2 hours, and the end point of the reaction was confirmed by gas chromatography.
- a solution obtained by dissolving 10.9 kg of sodium hydroxide in 246.3 kg of a 25% aqueous sodium hydroxide solution was added to adjust the pH to 11.7.
- the mixture was stirred at 45 to 47 ° C for 2 hours and separated.
- the aqueous layer was prepared by dissolving 31 kg of sodium hydroxide in 71 kg of a 25% aqueous sodium hydroxide solution.
- the solution was added, and the mixture was stirred and extracted with 461 kg of toluene at 23 to 24 ° C., and separated. Further, 461 kg of toluene was added to the aqueous layer, followed by stirring and extraction.
- the mixture was stirred at 135 to 137 ° C for 5 hours. After confirming the end point of the reaction by HP LC, the mixture was cooled to 80 ° C. Under reduced pressure of 6.5 to 2.7 kPa, 250 kg of dimethylformamide was distilled off at an internal temperature of 30 to 79 ° C. 226.3 kg of water was introduced, and the pH was adjusted to 8.2 by adding 35 kg of a 25% aqueous sodium hydroxide solution at 4 C. 41. At 1 ° C, 61.3 kg of ethyl acetate was added, and the mixture was extracted with stirring. The organic layer was washed with 5% saline, allowed to stand at 47 ° C, and separated.
- FIG. 1 shows a micrograph of the obtained 2- (4-methyl-2-phenylbiperazine-11-yl) —3-cyanoviridine oxalate.
- the physical properties are as follows.
- reaction solution was poured into 15 OmL of water, and extracted with 10 OmL of ethyl acetate.
- the organic layer was washed with 3 OmL of water, dried over anhydrous magnesium sulfate, and concentrated. Shrunk. Attempted crystallization with a solvent such as hexane, but did not crystallize.
- the 1-methyl-3-phenylbiperazine obtained by the production method of the present invention is a piperazine derivative useful as a production intermediate of mirtazapine and a substance which can be suitably used as a production intermediate thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002351528A CA2351528C (en) | 1999-09-30 | 2000-09-27 | Process for the preparation of a piperazine derivative |
JP2001526500A JP4330836B2 (ja) | 1999-09-30 | 2000-09-27 | ピペラジン誘導体の製造方法 |
DE60036076T DE60036076D1 (de) | 1999-09-30 | 2000-09-27 | Verfahren zur herstellung eines piperazinderivates |
AU74455/00A AU751629B2 (en) | 1999-09-30 | 2000-09-27 | Process for the preparation of a piperazine derivative |
EP00962874A EP1136470B1 (en) | 1999-09-30 | 2000-09-27 | Process for the preparation of a piperazine derivative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28037899 | 1999-09-30 | ||
JP11/280378 | 1999-09-30 | ||
JPPCT/JP00/05432 | 2000-08-14 | ||
PCT/JP2000/005432 WO2001025185A1 (fr) | 1999-09-30 | 2000-08-14 | Procede de production de derive de piperazine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001023345A1 true WO2001023345A1 (fr) | 2001-04-05 |
Family
ID=17624194
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005432 WO2001025185A1 (fr) | 1999-09-30 | 2000-08-14 | Procede de production de derive de piperazine |
PCT/JP2000/006650 WO2001023345A1 (fr) | 1999-09-30 | 2000-09-27 | Procede de preparation de derive piperazine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005432 WO2001025185A1 (fr) | 1999-09-30 | 2000-08-14 | Procede de production de derive de piperazine |
Country Status (8)
Country | Link |
---|---|
US (1) | US6495685B1 (ja) |
EP (1) | EP1136470B1 (ja) |
JP (3) | JP4330836B2 (ja) |
AT (1) | ATE370736T1 (ja) |
AU (2) | AU6476300A (ja) |
CA (1) | CA2351528C (ja) |
DE (1) | DE60036076D1 (ja) |
WO (2) | WO2001025185A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006022182A1 (ja) * | 2004-08-24 | 2006-03-02 | Sumitomo Chemical Company, Limited | 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 |
LT5382B (lt) | 2003-07-10 | 2006-11-27 | Akzo Nobel N. V. | ENANTIOMERISKAI GRYNO MIRTAZAPINO GAVIMO BuDAS |
JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
WO2008125578A2 (en) | 2007-04-11 | 2008-10-23 | N.V. Organon | A method for the preparation of mirtazapine |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
JP5080050B2 (ja) * | 2005-09-26 | 2012-11-21 | 住友化学株式会社 | 光学活性なピペラジン化合物の製造方法 |
US20090275749A1 (en) * | 2005-09-26 | 2009-11-05 | Hiroshi Maeda | Production method of optically active piperazine compound |
CN101304988A (zh) * | 2005-11-14 | 2008-11-12 | 住友化学株式会社 | 制备2-(4-甲基-2-苯基哌嗪-1-基)吡啶-3-甲醇的方法 |
CN101440067B (zh) * | 2007-11-21 | 2010-08-25 | 上海津力化工有限公司 | 一种药物中间体1-甲基-3-苯基哌嗪的制备方法 |
EP3026049B1 (en) | 2013-07-25 | 2021-09-22 | Dong-A ST Co., Ltd. | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate |
CN103509000A (zh) * | 2013-10-21 | 2014-01-15 | 山东鲁药制药有限公司 | 一种药物中间体1-(3-氰甲基吡啶基-2)-4-甲基-2-苯基哌嗪的合成方法 |
CN109988148A (zh) * | 2018-01-02 | 2019-07-09 | 北京哈三联科技有限责任公司 | 1-(3-氰基吡啶-2)-2-苯基-4-甲基哌嗪草酸盐的制备方法 |
CN114878727B (zh) * | 2022-05-06 | 2023-07-25 | 合肥高尔生命健康科学研究院有限公司 | 一种测定烟草中噁霉灵残留物的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4417388B1 (ja) * | 1967-06-29 | 1969-07-31 | ||
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
US4217452A (en) * | 1974-02-09 | 1980-08-12 | Akzona Incorporated | Synthesis for the preparation of tetracyclic compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1181322A (en) | 1967-06-29 | 1970-02-11 | Chugai Pharmaceutical Co Ltd | Piperazine Derivatives and processes for preparing the same |
NL179906C (nl) | 1974-02-09 | 1986-12-01 | Akzo Nv | Werkwijze voor het bereiden van 1,2,3,4,10,14b-hexahydrodibenzo(c,f)pyrazino (1,2-a)azepine derivaten. |
JPS5315520A (en) | 1976-07-28 | 1978-02-13 | Chino Kiki Seisakushiyo Kk | Transformer protector |
JPS5942678A (ja) | 1982-09-03 | 1984-03-09 | Akai Electric Co Ltd | 磁気記録再生装置における編集方法 |
FR2573075B1 (fr) * | 1984-09-14 | 1987-03-20 | Innothera Lab Sa | Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique |
US4772705A (en) | 1985-07-25 | 1988-09-20 | Pennwalt Corporation | Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines |
RU2001128228A (ru) | 1999-04-19 | 2003-07-20 | Тева Фармасьютикал Индастриз Лтд. (Il) | Новый синтез пиперазинового кольца |
-
2000
- 2000-08-14 AU AU64763/00A patent/AU6476300A/en not_active Abandoned
- 2000-08-14 WO PCT/JP2000/005432 patent/WO2001025185A1/ja active Application Filing
- 2000-09-27 AT AT00962874T patent/ATE370736T1/de not_active IP Right Cessation
- 2000-09-27 AU AU74455/00A patent/AU751629B2/en not_active Ceased
- 2000-09-27 DE DE60036076T patent/DE60036076D1/de not_active Expired - Fee Related
- 2000-09-27 CA CA002351528A patent/CA2351528C/en not_active Expired - Fee Related
- 2000-09-27 EP EP00962874A patent/EP1136470B1/en not_active Expired - Lifetime
- 2000-09-27 JP JP2001526500A patent/JP4330836B2/ja not_active Expired - Fee Related
- 2000-09-27 WO PCT/JP2000/006650 patent/WO2001023345A1/ja active IP Right Grant
- 2000-10-27 US US09/697,140 patent/US6495685B1/en not_active Expired - Fee Related
-
2008
- 2008-10-09 JP JP2008262502A patent/JP5161023B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-18 JP JP2012231010A patent/JP5656952B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4417388B1 (ja) * | 1967-06-29 | 1969-07-31 | ||
US4217452A (en) * | 1974-02-09 | 1980-08-12 | Akzona Incorporated | Synthesis for the preparation of tetracyclic compounds |
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT5382B (lt) | 2003-07-10 | 2006-11-27 | Akzo Nobel N. V. | ENANTIOMERISKAI GRYNO MIRTAZAPINO GAVIMO BuDAS |
US8058436B2 (en) | 2003-07-10 | 2011-11-15 | N.V. Organon | Method for the preparation of enantiomerically pure mirtazapine |
WO2006022182A1 (ja) * | 2004-08-24 | 2006-03-02 | Sumitomo Chemical Company, Limited | 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 |
JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
WO2008125578A2 (en) | 2007-04-11 | 2008-10-23 | N.V. Organon | A method for the preparation of mirtazapine |
Also Published As
Publication number | Publication date |
---|---|
JP2009167166A (ja) | 2009-07-30 |
WO2001025185A1 (fr) | 2001-04-12 |
US6495685B1 (en) | 2002-12-17 |
JP5656952B2 (ja) | 2015-01-21 |
JP5161023B2 (ja) | 2013-03-13 |
CA2351528C (en) | 2005-11-29 |
ATE370736T1 (de) | 2007-09-15 |
JP4330836B2 (ja) | 2009-09-16 |
DE60036076D1 (de) | 2007-10-04 |
EP1136470A4 (en) | 2004-09-22 |
EP1136470A1 (en) | 2001-09-26 |
AU751629B2 (en) | 2002-08-22 |
EP1136470B1 (en) | 2007-08-22 |
AU6476300A (en) | 2001-05-10 |
JP2013040196A (ja) | 2013-02-28 |
AU7445500A (en) | 2001-04-30 |
CA2351528A1 (en) | 2001-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5656952B2 (ja) | ピペラジン誘導体蓚酸塩結晶 | |
DK1797037T3 (en) | PROCESS FOR THE PREPARATION OF 4- {4 - [({[4-chloro-3- (trifluoromethyl) phenyl] AMINO} CARBONYL) AMINO] PHENYOXY} N-methylpyridine-2-carboxamide | |
CA2988594C (en) | Methods of making protein deacetylase inhibitors | |
JP2014516072A (ja) | アピキサバン製造方法 | |
EP2736905A1 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
WO2015124764A1 (en) | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate | |
EP1741700B1 (en) | Process for the preparation of carvedilol | |
WO2006006184A2 (en) | A process for the manufacturing of loratadine and its intermediates | |
WO2006022182A1 (ja) | 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 | |
JP3907787B2 (ja) | 安息香酸誘導体の製造方法 | |
JP4848704B2 (ja) | 2−(4−メチル−2−フェニルピペラジン−1−イル)−3−シアノピリジンの製造方法 | |
US8815870B2 (en) | 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof | |
CA2778807A1 (en) | Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone | |
MXPA02007060A (es) | Procedimiento para la obtencion de compuestos heterociclicos. | |
US7214796B2 (en) | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | |
JP2002338558A (ja) | (4−アルキル−1−ピペラジニルメチル)安息香酸誘導体の製造方法 | |
KR100566562B1 (ko) | 수마트립탄의 제조방법 | |
MXPA03009946A (es) | Nuevos procedimientos para la preparacion de compuestos de adenosina e intermedios para los mismos. | |
KR101298046B1 (ko) | 솔리페나신과 이의 염의 효율적 제조방법 | |
JP2010526126A (ja) | バルサルタンの製造方法 | |
KR20180018697A (ko) | 테리플루노미드의 신규한 제조 공정 | |
JP2004075616A (ja) | 4−ハロゲノ−2−(4−フルオロフェニルアミノ)−5,6−ジメチルピリミジンの製造方法 | |
WO2001004088A1 (fr) | Procede de preparation de derives d'amiline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 526500 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 74455/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2351528 Country of ref document: CA Ref country code: CA Ref document number: 2351528 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000962874 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2000962874 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 74455/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000962874 Country of ref document: EP |